Immune system overhaul: could CAR T-Cells tame autoimmune disease?
NCT ID NCT06152172
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them back as a one-time infusion. The main goal is to see if it is safe and tolerable, with a small group of 24 participants being followed for two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KYV-101 (a CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could point toward a new treatment option for people with severe autoimmune diseases that are not controlled by current therapies.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so it is too soon to know if it works. There are also risks from the chemotherapy given beforehand and potential side effects from the cell therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the Universithy of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States